Vimarsana
Biggest News Aggregation in the World

Breakthrough Device Designation Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breakthrough Device Designation Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breakthrough Device Designation Program Today - Breaking & Trending Today

Digital Health Market: Focus on Digital Therapeutics, - Vimarsana News

Digital Health Market: Focus on Digital Therapeutics,

INTRODUCTION. Digital Therapeutics, popularly known as DTx, represent a digital health solution which delivers medical interventions directly to the...

Digital Health Global Market Report 2023: Post-Pandemic - Vimarsana News

Digital Health Global Market Report 2023: Post-Pandemic

Dublin, Jan. 31, 2023 (GLOBE NEWSWIRE) -- The "Digital Health Market: Focus on Digital Therapeutics, Distribution by Type of Solution, Type of Therapy,...

Digital Health Global Market Report 2023: Featuring Ampersand Health, Livongo Health, CogniFit, JOGO Health & More - Vimarsana News

Digital Health Global Market Report 2023: Featuring Ampersand Health, Livongo Health, CogniFit, JOGO Health & More

/PRNewswire/ -- The "Digital Health Market: Focus on Digital Therapeutics, Distribution by Type of Solution, Type of Therapy, Purpose of Solution, Type of...

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC - Vimarsana News

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

/PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy...

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC - Vimarsana News

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

/PRNewswire/ -- Alpha Tau Medical Ltd. (Nasdaq: DRTS and DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy...